KOURIE Hampig Raphael

MD, MSC, MBIOETHICS
  • Medical and Research Activity

Oncogenetician

Unité De Génétique Médicale

Faculty of medicine, Saint Joseph University, Beirut, Lebanon (Since May 2017)

Hematologist-Oncologist

Bellevue Medical Center, Beirut, Lebanon

(Since December 2018)

Hotel-Dieu de France Hospital, Beirut, Lebanon

(Since April 2018)

Hôpital Saint Joseph des Sœurs de la Croix, Beirut, Lebanon

(Since September 2017)

 

  • Education

Subspecialty in GI oncology

Hôpital Européen Georges Pompidou, Paris, France

Post-Doctoral specialization in HEMATO-ONCOLOGY

Jules Bordet Institute, Brussels, Belgium

Post-Doctoral specialization in HEMATO-ONCOLOGY

Saint-Joseph University Faculty of Medicine, Beirut, Lebanon

Masters in Bioethics

University of Paris Descartes, Faculty of medicine, Paris, France

Inter-University degree in Digestive Oncology

University Paris Descartes, Faculty of medicine, Paris, France

Inter-University degree in Oncogenetics

University Paris Diderot, Faculty of medicine, Paris, France

Inter-University degree in Cytogenetics

University Grenoble Alpes, Grenoble, France

Fellowship in Medical Oncology

2014-2015/2015-2016

Jules Bordet Institute, Brussels, Belgium

Medical Doctor (MD)

2010

Saint-Joseph University Faculty of Medicine, Beirut, Lebanon

Masters in Medical and Biological Sciences

2008

Saint-Joseph University Faculty of Medicine, Beirut, Lebanon

Lebanese Scientific Baccalaureate Degree

2003

Honors: Very Good

Secondary School Graduate

2003

Stes Hripsimiantz School of Armenian Catholic Sisters, Fanar, Lebanon

 

  • Awards and Distinctions

Member of ESMO (European society of medical oncology) membership committee 2016-2018

FRON (Forum de recherche en oncologie) Award 2014 for the highest number of publications from Saint Joseph University , Beirut , Lebanon

FOSFOM (Fonds de Soutien à la Formation Médicale) Award 2015 for the best fellow of Université Libre de Bruxelles , Belgium

FRON Award (Forum de recherche en oncologie) 2015 for the highest number of publications from Saint Joseph University , Beirut , Lebanon

AMAAC (Arab medical association against cancer) award 2016 for the best young arab researcher

 

  • Published Research Work
  • Prévalence de l’abus physique et moral parmi les élèves libanais dans les établissements Bcherraoui C, Kouriye HR, Adib S. la revue de santé de la Méditerranée orientale, Vol 18 , No.10, 2012 .
  • Double pancreatic and gastric adenocarcinomas: A rare Kourie HR, Markoutsaki N, Roussel H, Rahmi G, Van der Stiegel M, Palazzo L, Fabre M, Cuenod CA,Dubreuil O, Landi B, Rougier P, Taieb J. Clin Res Hepatol Gastroenterol 2012.
  • Letrozole Efficacy in the treatment of Granulosa Tumor of the Ovary: A case Kourie HR, Kattan J, Antoun J , Sleilaty F. Onkologie 2013.
  • Optimum Chemotherapy in the management of metastatic pancreatic Ghosn M, Kourie HR, Elkarak F, Hanna C , Antoun J, Nasr D. World journal of gastroenterology 2014.
  • The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report. Kattan J, Kourie HR. Investigational new drugs 2014.
  • Type distribution of lymphomas in Lebanon: five- year single institution experience. Sader- Ghorra C, Rassy M, Naderi S, Kourie HR, Kattan
    1. Asian Pacific Journal of Cancer Prevention 2014.
  • Successful treatment of Evans syndrome with Tabchi S, Hanna C, Kourie HR, Aftimos P, El Osta L, Ghosn M. Investigational new drugs 2014
  • Outcome of breast cancer screening: a Lebanese single institution experience Kourie HR, Daher A, Matar D, Antoun J, Salloum L, Kattan Asian Pac J Cancer Prev 2015
  • Successful Eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease El Rassy E, Kourie HR, Nehme W, Georges S, Haddad E, Nasnas R, Nasr Clin Res Hepatol Gastroenterol. 2015.
  • Kidney cancer in Lebanon: a specific histological distribution? Khafaja S, Kourie HR, Matar D, Sader-Ghorra C, Kattan J. Asian Pac J Cancer Prev. 2015.
  • Anal cancer treatment: Current status and future Ghosn M, Kourie HR, Abdayem P, Antoun J, Nasr D. World J Gastroenterol. 2015
  • Factor XIII deficiency revealed by spontaneous intramedullary hemorrhage: confirmation of a severe Rassy EE, Kourie HR, Antoun J, Chouery E, Megarbane A, Nasr F. Blood Coagul Fibrinolysis. 2015
  • Optimum chemotherapy for the management of advanced biliary tract Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, Hanna C, Nasr D.World J Gastroenterol. 2015
  • Vulvar metastasis from bladder Aoun F, El Rassy E, Kourie HR, Hawaux E, van Velthoven R.Case Rep Obstet Gynecol. 2015
  • BRAF (V600) mutant non-small-cell lung cancer resistant to Karak FE, Assi T, Kourie HR, Rassy EE, Chebib R, Ghor M, Tabchi S. Int J Clin Exp Pathol. 2015
  • Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Kourie HR, Antoun J, Schakal A, Nasr E, Sahyoun M, Kattan J. Case Rep Ophthalmol Med. 2015
  • Histologic Distribution of Pulmonary Tumors in Lebanon: A 5-Year Single Institution Kourie HR, Rassy M, Ghorra C, Naderi S, Kattan J. Asian Pac J Cancer Prev. 2015
  • Novel mechanisms and approaches in the medical therapy of solid cancers.Awada G, Kourie HR, Awada AH. Discov Med. 2015
  • EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution Naderi S, Ghorra C, Haddad F, Kourie HR, Rassy M, El Karak F, Ghosn M, Abadjian G, Kattan J. Cancer Epidemiol. 2015
  • Comment on ‘Failure of intravitreal bevacizumab in the treatment of choroidal metastasis’. Kourie HR, Antoun J, Kattan Eye (Lond). 2015
  • Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers ? Kourie HR, Awada AH Future Oncol 2015
  • Pancreatic small cell El Rassy E, Tabchi S, Kourie HR, Assi T, Chebib R, Farhat F, Kattan J. Clin Res Hepatol Gastroenterol. 2015
  • Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors? Kourie HR, Awada G, Awada A Future Oncol. 2015
  • Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature Kourie HR, Antoun J, El Rassy E, Rassy M, Sader- Ghorra C, Kattan J. J Bone Oncol. 2015
  • Acquired factor inhibitor in a patient with monoclonal gammopathy of undetermined significance responding to Rassy EE, Tabchi S, Haddad FG, Chebib R, Assi T, Kourie HR, Nasr F. Blood Coagul Fibrinolysis. 2015
  • Checkpoint inhibitors in bladder and renal cancers: results and Aoun F, Kourie HR, Sideris S, Roumeguère T, Velthoven Rv, Gil
    1. T. Immunotherapy. 2015
  • Trends in mammography utilization for breast cancer screening in a Middle-Eastern country: Lebanon 2005-2013. Haddad FG, Kourie HR, Adib SM. Cancer Epidemiol. 2015
  • Validation of the EORTC QLQ-INFO 25 questionnaire in Lebanese cancer patients: Is ignorance a Bliss? Tabchi S, El Rassy E, Khazaka A, El Karak F, Kourie HR, Chebib R, Assi T, Ghor M, Naamani L, Richa S, Ghosn M, Kattan
    1. J. Qual Life Res. 2015
  • Watch and Wait in Lebanese Chronic Lymphocytic Leukemia Patients: How Relevant is it? Lutfallah AA, Kourie HR, Eid R, Farhat F, Ghosn M, Kattan J.Asian Pac J Cancer Prev. 2016
  • Improved Survival of Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis. Kourie HR, Ameye L, Paesmans M, Bron D. Clin Lymphoma Myeloma Leuk. 2016
  • Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design. Kourie HR, Aoun F. Invest New Drugs. 2016
  • Is metastatic pancreatic cancer an untargetable malignancy? Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. World J Gastrointest Oncol. 2016
  • Metastatic gastric cancer treatment: Second line and Ghosn M, Tabchi S, Kourie HR, Tehfe M. World J Gastroenterol. 2016
  • Express approval of immune checkpoint inhibitors: a conflict between science and Kourie HR, Tabchi S , Kattan J . Future Oncology 2016
  • Learning from the “tsunami” of immune checkpoint inhibitors in 2015. Kourie HR, Awada G, Awada Critical Reviews in Oncology-hematology. 2016
  • Managing Hodgkin lymphoma without chemotherapy: a novel, yet ‘welcomed’, challenge. Kourie HR, Tabchi S, Kattan J. Future Oncology 2016
  • Side-effects of checkpoint inhibitor-based combination therapy. Kourie HR, Klastersky J. Current Opinion in Oncology 2016.
  • Rare side-effects of checkpoint Kourie HR, Awada G , Awada
    1. Current Opinion in Oncology 2016.
  • Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 Kourie HR , Chaix M , Gombos A , Aftimos P , Awada A . Expert Opinion in drug metabolism and toxicology 2016.
  • Immune checkpoint inhibitors side effects and Kourie HR, Klastersky J. Immunotherapy 2016.
  • Improved survival in patients with CALR1compared to CALR2 mutated primary myelofibrosis: a meta-analysis. Kourie HR, Ameye L, Paesmans M, Bron D. British Journal of Haematology 2016.
  • Are virus-induced cancers more sensitive to checkpoint inhibitors? Kanaan H, Kourie HR, Awada A . Future Oncology 2016.
  • Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic Tabchi S, Kourie HR , Kattan J . Investigational new drugs 2016.
  • Road map for pain management in pancreatic cancer: A Lahoud MJ, Kourie HR , Antoun J , El Osta L , Ghosn M . World Journal of Gastrointestinal oncology 2016.
  • Bladder and vaginal transitional cell carcinoma: A case Aoun F, Kourie HR, El Rassy E, van Velthoven R. Oncology Letters 2016.
  • Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma? Kourie HR, Gharios J, Kattan J . Future Oncol 2016
  • Targeting EGFR mutation in non-small-cell lung cancer: challenges and future Haddad FG, Kourie HR, Kattan J. Future Oncology 2016.
  • Biomarkers for adverse events associated with immune checkpoint inhibitors. Kourie HR, Paesmans M, Klastersky J. Biomarker medicine 2016.
  • Mesotheliomas in Lebanon: Witnessing a Change in Kattan J, Eid R, Kourie HR, Farhat F, Ghosn M, Ghorra C, Tomb R. Asian Pacific Journal of Cancer Prevention 2016
  • Re: Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Kourie HR, Ameye L, Paesmans M, Bron
    1. D. Annals of hematology 2016.
  • Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F, Nasr D. World Journal of gastrointestinal oncology 2016.
  • Dermatologic adverse events of checkpoint inhibitors: what an oncologist should Habre M , Habre SB , Kourie HR. Immunotherapy 2016
  • Immune checkpoint inhibitors renal side effects and Rassy EE, Kourie HR, Rizkallah J, Karak FE, Hanna C, Chelala DN, Ghosn M. Immunotherapy. 2016
  • Concurrent driver mutations/rearrangements in non-small-cell lung cancer. Tabchi S, Kourie HR, Klastersky Current Opinion in Oncology 2017
  • Dilemma of first line regimens in metastatic pancreatic Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan
    1. J. World Journal of Gastroenterology 2016
  • Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature Simon A, Kourie HR, Kerger J.Chinese Journal of Cancer. 2017
  • Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. ESMO Open. 2016
  • Checkpoint inhibitors in the treatment of brain metastases of non-small- cell lung cancer and Kourie HR, Kanaan H, Awada G, Awada AH. Future Oncology. 2017
  • Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Chelala E, Arej N, Antoun J, Kourie HR, Zaarour K, Haddad FG, Farhat F, El Karak F, Kattan J Chemotherapy. 2017
  • Immunotherapies in sarcoma: Updates and future Ghosn M, El Rassy E, Kourie HR. World Journal of Clinical Oncology 2017
  • Physical long-term side-effects in young adult cancer survivors: germ cell tumors model. Kourie HR, Klastersky JA. Current Opinion in Oncology. 2017
  • Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.Kourie HR, Tabchi S, Ghosn M.World Journal of Gastroenterology. 2017
  • Unusual presentation of nasopharyngeal carcinoma with rectal Vogel M, Kourie HR, Piccart M, Lalami Y.World Journal of Clinical Cases.
  • The second wave of immune checkpoint inhibitor tsunami: advance, challenges and Kourie HR, Awada G, Awada A. Immunotherapy. 2017
  • Emerging treatments for HER2-positive early- stage breast cancer: focus on Kourie HR, El Rassy E, Clatot F, de Azambuja E, Lambertini M. Onco Targets and Therapeutics. 2017
  • Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole. Assi T, Kourie HR, El Rassy E, Moussa T, Kattan J. Anticancer Drugs. 2017
  • How and when adjuvant treatment should be intensified in stage III colorectal cancers? Saleh K, Khalife-Saleh N, Kourie HR, Chahine G. Future Oncol
  • Geriatric cancer trends in the Middle-East: Findings from Lebanese cancer projections until 2025.Haddad FG, Kattan J, Kourie HR, El Rassy E, Assi T, Adib SM.J Geriatr Oncol. 2018
  • Negative predictive biomarkers of checkpoint inhibitors in hyper- progressive tumors.Saleh K, Khalife-Saleh N, Haddad EE, Kourie HR. Biomark Med. 2017
  • Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer.Kourie HR, Mavroudakis N, Aftimos P, Piccart M. World J Clin Oncol. 2017
  • Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report. Mhamdi HA, Kourie HR, Jungels C, Aftimos P, Belbaraka R, Piccart-Gebhart M. J Med Case Rep. 2017
  • Electronic patient-reported outcomes: a revolutionary strategy in cancer care.Eid R, Haddad FG, Kourie HR, Kattan J.Future Oncol 2017
  • Impact of the new World Health Organization classification concept of neuroendocrine tumors.Rassy M, Kesrouani C, Kourie H, Kattan J, Ghorra
    1. C. Minerva Chir. 2018
  • Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent- Puig P. JAMA Oncol. 2017
  • Management of stage III non-small cell lung cancer.Tabchi S, Kassouf E, Rassy EE, Kourie HR, Martin J, Campeau MP, Tehfe M, Blais N. Semin 2017
  • Is gut microbiome a predictive marker to response to immune checkpoint inhibitors? Saleh K, Khalife-Saleh N, Kourie HR. I 2017
  • Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy? Saleh K, Khalifeh-Saleh N, Kourie HR, Nasr F, Chahine G. Immunotherapy 2018
  • Introduction to multidisciplinarity in neuro-oncology in Lebanon: First Annual Day of Neuro-Oncology. Kourie HR, Eid R, Kesserouany C, Abadjian G, Kattan J. Bull Cancer. 2018
  • Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression? Saleh K, Khalifeh-Saleh N, Kourie HR. 2018
  • New developments in the management of head and neck cancer – impact of pembrolizumab. Saleh K, Eid R, Haddad FG, Khalife-Saleh N, Kourie HR. Ther Clin Risk Manag. 2018
  • Do checkpoint inhibitors provide new hope for management of metastatic penile carcinoma? Eid R, Nemr E, Haddad FG, Kourie HR, Kattan J. Future 2018
  • The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. Kourie HR, Bakouny Z, Eid R, Haddad FG, Kattan J. Future Oncol. 2018
  • ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?Hobeika C, Rached G, Eid R, Haddad F, Chucri S, Kourie HR, Kattan J. Per Med. 2018
  • Urging medical students to publish: Advantages, disadvantages and new challenges.Rached G, Hobeika C, Karam E, Kourié HR, Kattan J. Bull Cancer. 2018
  • Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) reply. Kourie HR, Bakouny Z, Haddad FG, Eid R, Kattan J. Future Oncol. 2018
  • Where do immune checkpoint inhibitors stand in the management of thymic epithelial tumors?Saleh K, Khalifeh-Saleh N, Kourie HR. 2018
  • Prognostic and predictive biomarkers in nonmetastatic colorectal cancers.Haddad FG, Eid R, Kourie HR, Barouky E, Ghosn M. Future Oncol. 2018
  • Souaid T, Hindy JR, Eid R, Kourie HR, Kattan J. Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful. Bull Cancer. 2018
  • Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. Rassy EE, Chebly A, Korban R, Semaan W, Bakouny Z, Assi T, Kourie HR, Karak FE, Chouery E, Kattan J. Int J Hematol Oncol. 2017
  • Skin adverse events in recently approved targeted therapies in solid malignancies.Habre M, Salloum A, Habre SB, Abi Chebl J, Dib R, Kourie HR. Future Oncol. 2019
  • Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. Semaan A, Haddad FG, Eid R, Kourie HR, Nemr E. Future Oncol. 2019
  • Saleh K, Khalife-Saleh N, Kourie HR. Do immune-related adverse events correlate with response to immune checkpoint inhibitors? Immunotherapy 2019
  • Saleh K, Khalife-Saleh N, Kourie HR. Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer. 2019
  • Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future? Hindy JR, Souaid T, Kourie HR. Future Oncol. 2019
  • Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. Kourie H, Auclin E, Cunha AS, Gaujoux S, Bruzzi M, Sauvanet A, Lourenco N, Trouilloud I, Louafi S, El-Hajjar A, Vaillant JC, Smith D, Touchefeu Y, Bachet JB, Pietrasz D, Taieb J. Clin Res Hepatol Gastroenterol. 2019
  • Ocular and orbital side effects of ALK inhibitors: a review article. Chelala E, Hoyek S, Arej N, Kattan J, Kourie HR, Baakliny J, Antoun J. Future Oncol. 2019
  • FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas. Hajjar AH, Eid R, Haddad FG, Kourie HR. Future Oncol. 2019
  • Triple-negative breast cancer: current perspective on the evolving therapeutic landscape.Mehanna J, Haddad FG, Eid R1, Lambertini M, Kourie HR. Int J Womens Health. 2019
  • TRK inhibitors: toward an era of agnostic targeted therapies in oncology. Saleh K, Khalifeh-Saleh N, Kourie HR. 2019
  • The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.Moujaess E, Haddad FG, Eid R, Kourie HR. 2019
  • PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. Akiki M, Haddad FG, Kourie HR.  Biomark Med. 2019
  • PARP inhibitors: a tsunami of indications in different malignancies. Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR. 2020.
  • Nizar Bitar, Joseph Kattan , Hampig Raphael Kourie, Deborah Mukherji, Nagi El Saghir. The Lebanese Society of Medical Oncology (LSMO) Statement on the Care of Patients With Cancer During the COVID-19 Pandemic. Future Oncol . 2020
  • Khalil Saleh, Nadine Khalifeh-Saleh  , Hampig Raphael Kourie. Acute Myeloid Leukemia Transformed to a Targetable Disease . Future Oncol . 2020
  • Clarisse Kattan , Hassan Badreddine , Elie Rassy , Hampig Raphael Kourie, Joseph Kattan. The Impact of the Coronavirus Pandemic on the Management of Cancer Patients in Lebanon: A Single Institutional Experience . Future Oncol . 2020
  • Ronaldo Elkaddoum, Fady Gh Haddad, Roland Eid, Hampig Raphael Kourie. Telemedicine for Cancer Patients During COVID-19 Pandemic: Between Threats and Opportunities . Future Oncol . 2020
  • Elissar Moujaess, Hampig Raphael Kourie , Marwan Ghosn. Cancer Patients and Research During COVID-19 Pandemic: A Systematic Review of Current Evidence . Crit Rev Oncol Hematol . 2020.

 

  • Posters
  • Vitreoretinal surgery with silicone oil injection in uncomplicated rhegmatogenous retinal detachment: clinical and intra-ocular pressure outcomes. Antoun J, Azar G, Jabbour E, Kourie HR, Jalkh A. Association for Research in Vision and Ophthalmology (ARVO)-2013
  • Supportive social care for oncologic patients in Lebanon: Family and volunteers single institution Kourie HR, Osta L, Achkar S, Antoun J, Faddoul S, Salameh O, Ghosn M. Multinational Association Of Supportive Care In Cancer (MASCC). 2013
  • Relationship between oral health perception and nutritional status in senior cancer patients ; preliminary results . El Osta,L.El Osta,H.R.Kourie,M.Hennequin,S.TubertA Jeannin,M.Ghosn. MASCC 2013
  • EGFR mutation incidence and characteristics in non-squamous lung carcinoma in the Lebanese Joseph Gergi Kattan, Fady Haddad, Hampig Raphael Kourie, Samah Naderi, Marc Rassy, Fadi Rafic El Karak… Marwan Ghosn, Claude Sader-Ghorra. ASCO 2015
  • Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational Karine Le Malicot, Ralyath Balogoun, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean-Luc Van Laethem, Claire Mulot, Olivier Bouche, Thomas Aparicio, Pierre Michel, Josef Thaler, John A. Bridgewater, Eric Van Cutsem, Géraldine Perkins, Ramon Salazar, Come Lepage, Pierre Laurent-Puig.ASCO 2017
  • Efficacy and tolerability of second-line intra-arterial 5FU or mitomycine C after intra-arterial oxaliplatin failure in patients with colorectal cancer and unresectable liver metastases. Simon Pernot, Guillaume Velut, Hampig Raphael Kourie, Gregory Amouyal, Marc Sapoval, Anne-Laure Pointet, Bruno Landi, Yosra Zaaimi, Céline Lepère, Olivier Pellerin, Julien Taieb. ASCO 2017
  • Outcome of patients with pancreatic adenocarcinoma with complete pathological response following neo-adjuvant therapy. R. Kourie, A. Sa Cunha, S. Pernot, R. Coriat, A. Sauvanet, N. Regenet, S. Louafi, J. Bachet, D. Pietrasz, J. Taieb. ESMO 2017
  • The results of 3000 Fit: A prospective study led at Saint Joseph University of Beirut. Ronaldo Elkaddoum, Roland Eid, Fady Haddad, Myrna Germanos, Cybel Mehawej, Hampig Raphael Kourie, Joseph Gergi Kattan. ASCO 2019
  • Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon. Roland Eid, Stephanie Hage, Ingrid Antonios, Rita Moussa, Makram Khoury, Fady Haddad, Hampig Raphael Kourie, Carole Kesrouani, Claude Ghorra, Gerard Abadjian, Joseph Gergi Kattan. ASCO 2019
  • Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women. Joseph Al Ajami, Nadine Jalkh, Ghadi Moubarak, Roland Eid, Fady Haddad, Joseph Gergi Kattan, Marwan Ghosn, David M. Atallah, Eliane Chouery Khoury, Hampig Raphael Kourie. ASCO 2019

Oral Communications

1)Cancer des adolescents et adultes jeunes au Liban . Hampig Raphael Kourie , Claude Ghorra , Gerard Abadjian , Myrna Germanos , Marwan Ghosn . Eurocancer 2012

2)Soins de Support : Approche Futuriste . Marwan Ghosn , Hampig Raphael Kourie , Yola Dakdouki , Joelle Antoun , Alain Daher. Eurocancer 2013

3)Le futur de l’oncologie et l’intégration des jeunes oncologues. Hampig Raphael Kourie . Congrès d’oncologie francophone 2014

4)Les Nouvelles chimiothérapies dans l’ère des thérapies ciblées . Hampig Raphael Kourie . Congrès d’oncologie francophone 2015

5)Calreticulin versus JAK2 mutation characteristics in essential thrombocytosis in Asian and non-Asian population: A meta-analysis . Pan-Arab Congress of cancer 2015

6)Heavily pretreated metastatic HER2 positive breast cancer . Hampig Raphael Kourie . ESO-ESMO Masterclass 2016 , Ermatingen , Switzerland

7)Castration failure of prostate cancer presented with hemorrhagic carcinomatous meningitis. Hampig Raphael Kourie. ESMO prostate preceptorship, Prague , Czech Republic , 2016

8)Heavily pretreated premenopausal HR+ MBC . Hampig Raphael Kourie . Breast Academy , 2016

9)Side effects of Checkpoint inhibitors. Hampig Raphael Kourie. Post-MASCC , Jules Bordet, Belgium , 2016

10)Relapsing ovarian granulosa cell tumor treated successfully with exemestane and everolimus. Hampig Raphael Kourie ESMO Ovarian Cancer Preceptorship , Prague , 2017

11)IHC versus NGS in the evaluation of MSI in colorectal cancers. Hampig Raphael Kourie , Lebanese Society of Medical Oncology Annual Congress , Beirut , 2017

12) Cytogenetics and molecular biology in Glial Tumors.  Hampig Raphael Kourie , Lebanese Society of Neurology meeting , Beirut , 2018

13) Breast Clinical Cases Presentation. Hampig Raphael Kourie ESMO Summit Middle East , Dubai , 2018

14) TMB : Next Generation Biomarker in the era of immunotherapies . Hampig Raphael Kourie , FLOM , Beirut , 2018

15) New Molecular Techniques in Oncology: Which test in which technique? A summary for Clinical Oncologist. Hampig Raphael Kourie, Lebanese Society of Medical of Oncology Annual Congress, Beirut , 2018

16) Emerging Biomarkers in colorectal cancers. Hampig Raphael Kourie, Lebanese Society of Medical Oncology CME , 2019

 

  • Teaching and Training Experience

Residency  (July 2010 – April 2017)

Jules Bordet Institute, Oncology department , Brussels , Belgium

Jules Bordet Institute, Hematology department , Brussels , Belgium

Hôpital Européen Georges Pompidou , digestive oncology department , Paris , France

Hôtel Dieu de France Hospital, Hemato-Oncology department , Beirut , Lebanon

Hôtel Dieu de France Hospital, pathology department , Beirut , Lebanon

Hôtel Dieu de France Hospital, Radiation oncology department , Beirut , Lebanon

Bellevue Medical center , ER department , Beirut , Lebanon

Saint Joseph Hospital , Hemato-Oncology department , Beirut, Lebanon

Saint Joseph Hospital , ER service , Beirut , Lebanon Hôtel Dieu de France Hospital, Infectious disease department , Beirut , Lebanon

Hôtel Dieu de France Hospital, Gastro-enterology department , Beirut , Lebanon

Hôtel Dieu de France Hospital, Endocrinology department, Beirut , Lebanon

Internship (July 2009 – December 2009)

Saint Joseph Hospital , General Surgery department , Beirut, Lebanon

Saint Joseph Hospital , Pneumology department , Beirut , Lebanon

Saint Joseph Hospital , ER department , Beirut , Lebanon Saint Joseph Hospital , Gastro-enterology department , Beirut , Lebanon

Saint Joseph Hospital , Neurology department , Beirut , Lebanon

Internship July 2008 – June 2009 , Jan 2010 , June 2010

Hôtel Dieu de France Hospital, Ophtalmology and ENT departments , Beirut , Lebanon

Hôtel Dieu de France Hospital, Pneumology department , Beirut, Lebanon

Hôtel Dieu de France Hospital, Intensive Care Unit department, Beirut Lebanon

Hôtel Dieu de France Hospital, AnathomoPathology department, Beirut , Lebanon

Hôtel Dieu de France Hospital, General Surgery department , Beirut , Lebanon

Hôtel Dieu de France Hospital, Infectious disease department , Beirut , Lebanon

Hôtel Dieu de France Hospital, Endocrinology department, Beirut , Lebanon

Hôtel Dieu de France Hospital, Pediatrics department , Beirut, Lebanon

Observership Aug. 2007

Hôtel Dieu de France Hospital, Urology and Endocrinology services, Beirut, Lebanon

Performed complete medical examination and history taking of patients and filled their medical reports.

Observership Aug. 2007

Yerevan University Hospital , Cardiology Departement , Yerevan , Armenia

Observed medical examination, history taking, diagnosis and treatment of patients.

Nursing Internship Aug. 2004

Hôtel Dieu de France Hospital, Beirut, Lebanon

Performed nursing functions at the hospital from taking vital signs, to preparing and administering medications, to catheterization

Red Cross First Aid Principles Training May 2004

University Saint Joseph, Beirut , Lebanon

 

  • Personal and Professional Development

Memberships, Organizations, and Community Service:

President of the alumni of Stes Hripsimiantz College   2003– 2004

Member of the Armenian Catholic University Students Association (the executive committee 2004 – 2005) Member of the Armenian Students Association in Saint

Joseph University (the executive committee 2004 – 2005) Class delegate for the academic year 2003-2004; 2004- 2005; 2005-2006

Vice-President of the medical Students’ Assembly of Faculty of Medicine of Saint Joseph University for the 2004-2005 academic year

President of the medical Students’ Assembly of Faculty of Medicine of Saint Joseph University for the 2005-2006 and 2006-2007 academic year

Coordinator of the SRC journal Hypocampus (the official journal of the students of faculty of medicine of Saint Joseph University) during 2005-2006 and 2006-2007 academic year

Member of the islamo-christian dialogue committee of the Saint Joseph University in 2006

Many radio interviews in Armenian during the awareness campaign of the ministry of public health for breast cancer

Young member of ESMO and AMAAC .

Member of  ESMO membership committee  (2016-2019 )

Languages

Arabic (Fluent), English (Fluent), French (Fluent), Armenian (Fluent)

Travel Abroad

France, Sweden, Finland, Italy, Armenia, Cyprus, Syria, Malta, Germany, United States, Qatar, Dubai, United Kingdom, South Korea

Computer Skill

Microsoft Office Suite, Adobe Photoshop, Adobe Illustrator, Macromedia Flash, and SPSS

Certified in Good Clinical Practice (GCP) in 2013

References are available upon request